VanDeVoorde René G
Division of Pediatric Nephrology and Hypertension, Cincinnati Children's Hospital Medical Center, Cincinnati, OH.
Pediatr Rev. 2015 Jan;36(1):3-12; quiz 13. doi: 10.1542/pir.36-1-3.
On the basis of strong research evidence, the prevalence of poststreptococcal glomerulonephritis (PSGN) is decreasing worldwide, although it still remains the leading cause of glomerulonephritis in children. The overall decrease in prevalence of PSGN has been mainly driven by a significant decrease in pyoderma seen in the last half-century, such that postpharyngitic PSGN is most commonly seen in developed nations. On the basis of primarily consensus because of a lack of relevant clinical studies, the latency period between streptococcal infection and the development of nephritis is a hallmark of PSGN, with this period lasting 1 to 2 weeks with pharyngeal infections or 2 to 6 weeks with skin infections. Concurrent infectious and nephritis symptoms should elicit further suspicion of other causes of glomerulonephritis. On the basis of expert opinion, PSGN is one of a handful of nephritic disorders with hypocomplementemia (low C3 level). The decrease in C3 is found in more than 90% of PSGN cases and is typically seen earlier than an increase in antistreptolysin O titers. Measuring C3 and C4 may also be helpful in the evaluation of other causes of acute nephritis. On the basis of primarily consensus because of a lack of relevantclinical studies, the main sequelae of PSGN (hypertension, edema,gross hematuria, and impaired renal function) are greatest in thefirst 7 to 10 days of disease. Therefore, this period requires themost vigilance for adverse effects. On the basis of some research evidence and consensus, the most effective treatment of hypertension and edema in PSGN is loop or thiazide diuretics, which may also address hyperkalemia. Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers may be effective in hypertension control but carry the risk of hyperkalemia and temporarily impairing recovery of renal function. On the basis of some research evidence and consensus, the prognosis for PSGN, even long term, is good. Despite being the most prevalent of the childhood glomerulonephritides, it often does not cause chronic kidney disease, but persistent microscopic hematuria and proteinuria may be seen in less than 10% of patients.
基于强有力的研究证据,尽管链球菌感染后肾小球肾炎(PSGN)仍是儿童肾小球肾炎的主要病因,但在全球范围内其发病率正在下降。PSGN发病率的总体下降主要是由上世纪后半叶脓疱病显著减少所致,因此咽后PSGN在发达国家最为常见。由于缺乏相关临床研究,主要基于共识,链球菌感染与肾炎发生之间的潜伏期是PSGN的一个标志,咽部感染时此期持续1至2周,皮肤感染时持续2至6周。同时出现感染和肾炎症状应进一步怀疑肾小球肾炎的其他病因。基于专家意见,PSGN是少数伴有低补体血症(C3水平低)的肾炎性疾病之一。超过90%的PSGN病例中可发现C3降低,且通常比抗链球菌溶血素O滴度升高出现得更早。检测C3和C4也有助于评估急性肾炎的其他病因。由于缺乏相关临床研究,主要基于共识,PSGN的主要后遗症(高血压、水肿、肉眼血尿和肾功能损害)在疾病的最初7至10天最为严重。因此,这一时期需要对不良反应保持最高警惕。基于一些研究证据和共识,PSGN中高血压和水肿最有效的治疗方法是袢利尿剂或噻嗪类利尿剂,它们也可解决高钾血症问题。血管紧张素转换酶抑制剂或血管紧张素受体阻滞剂可能对控制高血压有效,但有高钾血症风险并可能暂时损害肾功能恢复。基于一些研究证据和共识,PSGN的预后,即使是长期预后,也是良好的。尽管它是儿童期最常见的肾小球肾炎,但通常不会导致慢性肾病,但不到10%的患者可能会出现持续性镜下血尿和蛋白尿。